

REMARKS

The amendments introduce no new matter.

5 Paragraph (000148) has been amended to include the SEQ ID No. for the
amino acid sequence appearing in the last sentence of this paragraph. In
addition, Applicants provide herewith a Sequence Listing, which includes this
amino acid sequence.

Both a paper copy of the Sequence Listing and a copy in computer
readable form as required under 37 C.F.R. § 1.821(e) are also submitted
10 herewith. As required by 37 C.F.R. § 1.821(f), the data on the enclosed diskette
is identical to the paper Sequence Listing.

The claims are amended to remove paragraph numbers, focus the claims
on preferred and additional subject matter or to correct errors. Claims 22-40
Support for new claims 41-53 is found throughout the specification, including the
15 description at pages 47-80 (individual compounds), 153-154 (inflammation), 174-
176 (nonaqueous formulations) 173-174 and 182-184 (infections).

Please charge any additional fees, including any fees for additional
extension of time, or credit overpayment to Deposit Account No. 501536.

20 Respectfully submitted,

Hollis-Eden Pharmaceuticals, Inc.

25 Date: June 15, 2004

By: Daryl D Muenchau

Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
P: 858-320-2569
F: 858-558-6470

30